SEC Form 4 · accession 0001391045-15-000003
NephroGenex, Inc. · NRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pierre Legault
Officer — Chief Executive Officer · Director
Period of report
Apr 30, 2015
Accepted (ET)
May 4, 2015 · 4:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $7.31 | Apr 30, 2015 | A | 50,000 | A | Apr 30, 2016 | Apr 30, 2025 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F125% of the shares underlying the options will vest on April 30, 2016 and the remainder of the shares underlying the options will vest on a pro rata monthly basis for a three-year period following April 30, 2016.